[Featured Stock] NanoEntek Gains Attention on Potential Export of COVID-19 Diagnostic Kits

[Asia Economy Reporter Jang Hyowon] NanoEntek is showing strength following news of a sharp increase in confirmed cases of COVID-19 in the Seoul metropolitan area.

As of 9:14 AM on the 18th, NanoEntek is trading at 10,800 KRW, up 0.47% from the previous day.

On June 10th, NanoEntek announced that it had obtained export approval from the Ministry of Food and Drug Safety (MFDS) for its COVID-19 molecular diagnostic kit.

The product approved for export by NanoEntek uses the real-time RT-PCR method, which amplifies specific genes of the novel coronavirus. It enhances user convenience by enabling all processes from cDNA synthesis from RNA to PCR amplification to be performed in a single tube, and it can confirm infection status within 1 hour and 30 minutes, allowing for rapid large-scale testing.

Following the export of its COVID-19 antibody diagnostic kit ‘FREND COVID-19 IgG/IgM Duo,’ NanoEntek can now also export the molecular diagnostic kit ‘En-swer COVID-19 RT-PCT Kit,’ enabling tailored step-by-step responses suited to various purposes and environments in different countries.

Accordingly, the company expects strong sales of existing products in the second half of the year along with potential exports of COVID-19 diagnostic kits.

A company representative stated, “With positive potential factors such as additional approvals in North and South American regions including the United States, Brazil, and Mexico, as well as European regions like Belgium, stable performance growth due to increased related exports is expected.”

This content was produced with the assistance of AI translation services.